Harnessing graft-versus-malignancy: Non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy

British Journal of Haematology

Volumn 111, Issue 1, 2000, Pages 18-29

  Champlin, Richard ^a   Khouri, Issa ^a   Shimoni, Avichai ^a   Gajewski, James ^a   Kornblau, Steven ^a   Molldrem, Jeffrey ^a   Ueno, Naoto ^a   Giralt, Sergio ^a   Anderlini, Paolo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Allogeneic transplant; Leukaemia; Lymphoma; Non ablative

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; BONE MARROW TRANSPLANTATION; DISEASE PREDISPOSITION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC DISEASE; HEMATOPOIESIS; PRIORITY JOURNAL; REVIEW; WHOLE BODY RADIATION;

BONE MARROW TRANSPLANTATION; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; GRAFT VS TUMOR EFFECT; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOMA; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 0033768662     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2000.02196.x     Document Type: Review

References (129)

1. + donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant
2. Allogeneic stem cell transplantation with fludarabine based less intensive conditioning as adoptive immunotherapy in advanced Hodgkin's disease
3. Graft-versus-leukemia. No longer an epiphenomenon
4. Cytokine dysregulation and acute graft-versus-host disease
5. Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse
6. Philadelphia-positive metaphases in the marrow after bone marrow transplantation for chronic granulocytic leukemia
7. 1 T cells
8. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia
9. Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation
10. Allogeneic marrow transplantation for multiple myeloma: An analysis of risk factors on outcome
11. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia
12. + minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells
13. Antigen presentation: A balanced diet
14. Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells
15. Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias
16. Mini-allografts: Ongoing trials in humans
17. Attenuation of graft-versus-host disease and graft rejection by ex vivo immunotoxin elimination of alloreactive T cells in an H-2 haplotype disparate mouse combination
18. + T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation
19. Phase I/II study of thymidine kinase (tk)-transduced donor lymphocyte infusions (DLI) in patients with hematologic malignancies
20. Retention of graft-versus-leukemia using selective depletion of CD8 positive T lymphocytes for prevention of graft versus host disease following bone marrow transplantation for chronic myelogenous leukemia
21. Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: Evidence for a graft-versus-tumor effect
22. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses
23. Donor-recipient polymorphism of the proteinase 3 gene: A potential target for T-cell alloresponses to myeloid leukemia
24. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneie bone marrow transplantation
25. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation
26. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: Where we now stand
27. Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia
28. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose
29. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer
30. Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia
31. Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes
32. Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen specific cytotoxic T lymphocytes
33. Identical-twin (Syngeneic) marrow transplantation for hematologic cancers
34. Mechanisms of disease: Graft-versus-host disease
35. Evidence that large granular lymphocytes of donor origin mediate acute graft-versus-host disease
36. Cytokine storm of graft-versus-host disease: A critical effector role for interleukin-1
37. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma
38. How does bone marrow transplantation cure leukaemia?
39. Identical-twin bone marrow transplants for leukemia
40. Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear ceil preparations
41. Leukemia relapse after allogeneic bone marrow transplantation: A review
42. CD8+ depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Graft vs leukemia without graft versus host disease
43. Induction of graft-versus-leukemia as primary treatment of chronic myelogenous leukemia
44. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
45. Preliminary results of fludarabine/melphalan or 2CDA/melphalan as preparative regimens for allogeneic progenitor cell transplantation in poor candidates for conventional myeloablative conditioning
46. Non-myeloablative conditioning with fludarabine/ melphalan for patients with multiple myeloma
47. Graft-versus-leukaemia activity can be predicted by natural cytotoxicity against leukaemia
48. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk of relapse associated with T-cell depletion
49. The role of minor histocompatibility antigens in GVHD and rejection: A mini-review
50. Transplantation of anergic histoincompatible bone marrow allografts
51. Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia
52. Total body irradiation and acute graft-versus-host disease: The role of gastrointestinal damage and inflammatory cytokines
53. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation
54. Frequency of bone marrow T cells responding to HLA-identical non-leukemic and leukemic stimulator cells
55. Graft-versus-leukemia reactions after bone marrow transplantation
56. Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: Role of polymerase chain reaction in predicting relapse
57. Cellular and cytokine mediated effects of CD4-positive lymphocyte lines generated in vitro against chronic myelogeneous leukemia
58. Graft-versus-leukaemia following allogeneic bone marrow transplantation: Emergence of cytotoxic T lymphocytes reacting to host leukaemia cells
59. + T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen
60. Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus-host disease following allogeneic bone marrow transplantation
61. Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: Lack of residual donor hematopoiesis predicts aplasia
62. Reduction in the frequency of transplant-related complications in patients with chronic myeloid leukemia undergoing BMT preconditioned with a new, non-myeloablative drug combination
63. Engraftment and induction of GVL with fludarabine-based non-ablative preparative regimen in patients with chronic lymphocytic leukemia
64. Transplant Lite: Induction of graft-versus-leukemia using fludarabine-based non-ablative chemotherpy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies
65. Transplant-lite using fludarabine-cyclophosphamide and allogeneic stem cell transplantation for low grade lymphoma
66. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: Molecular remissions and evidence of graft-versus-malignancy
67. Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: Timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease
68. Low transplant related cute complications in patients with CML undergoing allogeneic stem cell transplantation with a low dose (550 cGy) total body irradiation conditioning regimen
69. Graft-vs-leukemia effect of donor lymphocyte transfusions in marrow grafted patients
70. T cell subsets and graft-versus-host disease
71. Variable capacity of L3, T4 + T cells to cause lethal graft versus host disease across minor histocompatibility barriers in mice
72. Detection of minimal residual disease by polymerase chain reaction of bcr/abl transcripts in chronic myelogenous leukaemia following allogeneic bone marrow transplantation
73. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation
74. Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia
75. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease
76. T-cell depletion of HLA-identical transplants in leukemia
77. Specific depletion of alloreactive T cells in HLA-identical siblings: A method for separating graft-versus-host and graft-versus-leukaemia reactions
78. Outpatient allografting with minimally myelosuppressive immunosuppressive conditioning of low-dose TBI and postgrafting cyclosporine and mycophenolate mofetil
79. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia
80. Targeted T-cell therapy for human leukemia: Cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells
81. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units
82. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia
83. Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir
84. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens
85. + cells for prevention of graft-versus-host disease after bone marrow transplantation: A randomized controlled trial
86. Cytogenetic analysis of chimerism and leukemia relapse in chronic myelogenous leukemia patients after T cell-depleted bone marrow transplantation
87. Donor leucocyte transfusions for relapse in myelodysplastic syndrome after allogeneic bone marrow transplantation
88. The role of CD4 and CD8 T cells in the graft-versus-leukemia response in Rauscher murine leukemia
89. Evidence for a possible role of Asialo-GM1-positive cells in the graft-versus-leukemia repression of a murine type-C retroviral leukemia
90. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: Freedom from relapse in the absence of graft-versus-host disease
91. Clinical significance of bcr-abl gene rearrangement detected by the polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia
92. Persistence of myeloid progenitor cells expressing BCR-ABL mRNA after allogeneic bone marrow transplantation for chronic myelogenous leukemia
93. Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation
94. The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation
95. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: Results and implications in 346 patients
96. Achievement of complete cytogenetic remission after two very low-dose donor leucocyte infusions in a patient with extensive cGVHD relapsing in accelerated phase post allogeneic BMT for CML
97. Sequential molecular monitoring of chimerism in chronic myeloid leukemia patients receiving donor lymphocyte transfusion for relapse after bone marrow transplantation
98. Antitumor protection using murine dendritic cells pulsed with acid-eluted peptides from in vivo grown tumors of different immunogenicities
99. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia
100. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation
101. - phenotype are effectors of experimental cutaneous graft-versus-host disease
102. Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction
103. CD8-Deplete donor lymphocyte infusion (DLI) fur the treatment of CML relapse after allogeneic transplant: Long term follow up and factors predicting outcome
104. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
105. Generation of leukemia-reactive cytotoxic T lymphocytes from HLA-identical donors of patients with chronic myeloid leukemia using modifications of a limiting dilution assay
106. Specific recognition of human leukemic cells by allogeneic T cells. II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cells
107. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation
108. Mixed hematopoietic chimerism after hematopoietic stem cell allografts
109. Mixed hematopoietic chimerism after marrow allografts - Transplantation in the ambulatory care setting
110. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms
111. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation
112. The role of bone marrow transplantation for eradication of malignant disease
113. Bone marrow transplantation for malignant disease
114. Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: An approach for specific in vivo donor T-cell depletion after bone marrow transplantation
115. Graft-versus-myeloma effect: Proof of principle
116. Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow
117. Photochemical treatment with S-59 psoralen and ultraviolet A light to control the fate of naive or primed T lymphocytes in vivo after allogeneic bone marrow transplantation
118. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer
119. Management of lymphoma recurrence after allogeneic transplantation: The relevance of graft-versus-lymphoma effect
120. Allogeneic bone marrow transplantation for low-grade lymphoma
121. Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones
122. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: The case for giving donor leukocyte transfusions before the onset of hematologic relapse
123. Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: Equal efficacy of lymphocytes from sibling and matched unrelated donors
124. Irradiated donor leukocytes promote engraftment of allogeneic bone marrow in major histocompatibility complex mismatched recipients without causing graft-versus-host disease
125. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
126. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution
127. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts
128. Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation
129. Allogeneic NK cells as potent antileukemic effector cells after allogeneic bone marrow transplantation in mice